

MEDETOMIDINE MIXED WITH OPIOIDS: THE SPECTRUM OF CLINICAL AND PUBLIC HEALTH IMPLICATIONS FROM OVERDOSE TO WITHDRAWAL

WD4994

PROGRAM DESCRIPTION: This recorded webinar is an overview of the clinical and public health implications of medetomidine involved opioid overdose and withdrawal.

OBJECTIVES:

At the conclusion of the activity, the participant will be able to:

1. Recognize when medetomidine is involved in an overdose.
2. Describe how medetomidine involvement in overdose affects patient management.
3. Describe management of withdrawal when medetomidine involvement is suspected.
4. List how public health professionals and clinicians have collaborated to address overdoses involving medetomidine.

**FACULTY/
CREDENTIALS:**

Arwady, Allison MD, MPH, Director, National Center for Injury Prevention, Centers for Disease Control and Prevention

Huo, Samantha MD, MPH, MS, Assistant Professor of Clinical Emergency Medicine, University of Pennsylvania Perelman School of Medicine

Perrone, Jeanmarie MD, FACMT, Professor, Emergency Medicine, Medical Toxicology and Addiction Medicine Initiatives Director, Center for Addiction Medicine and Policy, University of Pennsylvania Perelman School of Medicine

CE ORIGATION DATE:

08/07/2025

CE EXPIRATION DATE:

08/07/2027

URL

<https://cdc.gov/overdose-prevention/hcp/trainings/medetomidine.html>

INTENDED AUDIENCE:

Physicians and Registered Nurses

PREREQUISITES:

N/A

FORMAT:

This activity is Web on Demand

CONTACT INFORMATION:

CDC's CE Accreditation Team has a policy for grievances that is available upon request.

Office of CDC Division of Overdose Prevention 1- 800-232-4636

ACCREDITATION STATEMENTS:

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this **enduring** activity for a maximum of **1** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for **1** nursing contact hours.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

The Centers for Disease Control and Prevention (CDC) complies with applicable Federal civil rights laws and does not discriminate based on race, color, national origin, age, disability, religion, or sex. To learn more visit: <https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html>.

Instructions for Obtaining Continuing Education (CE)

WD4994- Medetomidine mixed with opioids: the spectrum of clinical and public health implications from overdose to withdrawal, please visit [CDC TRAIN](#) and search for the course in the Course Catalog using **WD4994**. Follow the steps below by **08/07/2027**.

1. Register for and complete the course.
2. Pass the post-assessment at **75%**
3. Complete the evaluation.
4. Visit Your Learning to access your certificates and transcript.

FEES: No fees are charged for CDC's CE activities.